Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

NCT03331198 is registered in ClinicalTrials.gov with Juno Therapeutics, a Subsidiary of Celgene as lead sponsor.

NCT NCT03331198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03331198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 27, 2017
Completion date
November 26, 2027
Enrollment
320 (estimated)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphocytic, chronic, b-cell, lymphoma, small lymphocytic